| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028919 |
| Receipt No. | R000032985 |
| Official scientific title of the study | Efficacy of CGS-1 in Migraine Female Volunteers: Randomized, Single-blind, Placebo-controlled, Crossover Trial |
| Date of disclosure of the study information | 2017/09/24 |
| Last modified on | 2018/04/04 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Efficacy of CGS-1 in Migraine Female Volunteers: Randomized,
Single-blind, Placebo-controlled, Crossover Trial |
|
| Title of the study (Brief title) | Efficacy of CGS-1 in Migraine | |
| Region |
|
|
| Condition | ||||
| Condition | Migraine | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To confirm the efficacy of CGS-1 for female migraine without aura. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Change in NRS (Numerical Rating Scale) from the start of the test to 30 minutes later. |
| Key secondary outcomes | 1)Change in NRS (Numerical Rating Scale) at 60 minutes, 120 minutes and 180 minutes after the start of the test.
2)Changes in daily disability assessment HIT (Headache Impact Test) - 6 |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Apply the CGS-1 for forehead for 2 hours. | |
| Interventions/Control_2 | Apply the placebo for forehead for 2 hours. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1)Women aged 20-49.
2)Subjects with migraine without aura experience three to five migraine per month. 3)Subjects with lucidity and no intellectual disability can communicate. 4)Written informed consent. 5)If migraine and tension type headache are merged, the subjects can distinguish between the two. |
|||
| Key exclusion criteria | 1)Subjects with migraine with aura
2)Subjects with the headache without migraine 3)Subjects with taking triptan medicine. 4)Subjects with the hemicrania continua. 5)Subjects with pregnancies and lactations. 6)Subjects with atopic dermatitis. 7)Subjects with vulnerable to skin irritation by menthol or alcohol. 8)Subjects deemed inappropriate to participate in this study by the principle investigator |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Nobuyasu Kimura |
| Organization | Tokyo Clinic |
| Division name | Pain Clinic of Internal Medicine |
| Address | 2-2-1, Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan |
| TEL | 03-3516-7151 |
| kimukimu1234@hotmail.co.jp | |
| Public contact | |
| Name of contact person | Nobuyasu Kimura |
| Organization | Tokyo Clinic |
| Division name | Pain Clinic of Internal Medicines |
| Address | 2-2-1, Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan |
| TEL | 03-3516-7151 |
| Homepage URL | |
| kimukimu1234@hotmail.co.jp | |
| Sponsor | |
| Institute | Kao Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Tokyo Clinic
|
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人財団 健貢会 東京クリニック(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032985 |